Talphera

Official Twitter account of Talphera, Inc. a company developing and commercializing innovative therapies for use in medically supervised settings.

[LifeSci Advisors @LifeSciAdvisors]

Please join us for the @acelrx_pharma KOL Webinar on AcelRx's Nafamostat Program featuring International Kidney Disease Experts Stuart Goldstein, MD and Lakhmir Chawla, MD. A live Q&A session will follow. Register here: https://t.co/Hdc1HEHpdQ

[Talphera @talphera]

FOR INVESTOR USE:
Newest Battlefield Opioid, Sublingual Sufentanil: A Proposal to Refine Opioid Usage in the U.S. Military https://t.co/0eP1braijA

[Talphera @talphera]

FOR INVESTOR USE:
Sufentanil sublingual may lower opioid use after THA, TKA https://t.co/twhulF0g6U

[Talphera @talphera]

#AADPAC has voted in favor of recommending #FDA approval of $ACRX investigational therapy to treat moderate-to-severe #acutepain in medically supervised settings. News release: https://t.co/CyFCOeRVP7

[Talphera @talphera]

We reported top-line IAP312 results & 2Q financials. Both will be discussed on our 8:30 am conf call / webcast: https://t.co/8pXZPUI8U7

[Talphera @talphera]

ZALVISO has been awarded the prestigious @RedDot Award. #reddotaward https://t.co/DHDTQr6aJF

[Talphera @talphera]

$ACRX 1Q Results reported: https://t.co/4KnUXeVxAn. Webcast and conference call in 26min: https://t.co/7vePhYHrbl

[Talphera @talphera]

2 analyses of IV, transdermal and sublingual PCA systems are published in @CMRO_Journal: https://t.co/zYy8nvqovv & https://t.co/cftdEFnCua

[Talphera @talphera]

if you missed our moderated e-poster at the @ASRA_Society #ASRASpring17 meeting, you may find it on our website: https://t.co/zY9lL5l638

[Talphera @talphera]

Come see comprehensive efficacy and integrated safety data from DSUVIA clinical program at #ASRASpring17 in e-poster today at 3:45 - Salon 5

[Talphera @talphera]

@TheMicroCapConf, thanks for the invite; we’re looking forward to presenting on the 4th. https://t.co/oUjsm9yj4D $ACRX

[Talphera @talphera]

MAA for $ACRX's ARX-04 sufentanil sublingual tablet (called DSUVIA in US) under review at EMA. Details in release: https://t.co/7og0ng8GHu

[Talphera @talphera]

$ACRX hosting 1x1s April 19 at the European Smallcap Event hosted by CF&B. Go to https://t.co/Tp0AjBJ9A7 to register and book a meeting

[Talphera @talphera]

Results from SAP302 study of mod-to-severe acute pain in ER pts being presented at @ISICEM. Come by poster P272 to learn more

[Talphera @talphera]

$ACRX presenting at Oppenheimer HC Conf on 3/22 at 10:55am. If you can’t meet us there, a webcast is avail: https://t.co/FzMNP8Cp6R

[Talphera @talphera]

@MarketJane on FDA’s acceptance of DSUVIA NDA for mod-sev acute pain: https://t.co/GcGaG0hetP. FDA expects to render decision by Oct 12

[Talphera @talphera]

NDA for @AcelRx_Pharma’s DSUVIA accepted for filing by FDA. Release here: https://t.co/7kMXjyVuau

[Talphera @talphera]

Were u unable to attend @_smallcapnation Family Office & LS Symposium? See @MarketJane interview w us on YouTube: https://t.co/Y0y9z399R4

[Talphera @talphera]

More about the @_smallcapnation Family Office Symposium explained here: https://t.co/V6NB6f41KN

[Talphera @talphera]

T Morris & G Ford w @MarketJane 2/21 (3:20-4:20) during Family Office Symposium by @_smallcapnation. Eventbrite tix: https://t.co/JbflrDL26i